Cargando...

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape

Follicular lymphoma (FL) is the second most common type of non-Hodgkin’s lymphoma. FL is an incurable disease with treatment options ranging from a “watch-and-wait” approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Manag Res
Main Authors: Subramanian, Janakiraman, Cavenagh, Jamie, Desai, Bhardwaj, Jacobs, Ira
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2017
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5411111/
https://ncbi.nlm.nih.gov/pubmed/28479860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S120589
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!